Risks

Extended reimbursement and adoption cycles can delay revenue conversion, and RADX’s working-capital intensity appears worse than most diagnostics peers with faster cash collection.

Negative interest coverage despite minimal net debt suggests earnings volatility can constrain financing flexibility, while better-capitalized peers retain more room to absorb demand swings.

Very high days sales outstanding indicates customer payment timing risk can pressure liquidity and working capital, whereas peers with shorter collection cycles convert sales to cash more efficiently.

Opportunities

Low net debt relative to EBITDA provides balance-sheet flexibility to support commercial expansion, while more leveraged peers have less room to fund growth through cycles.

Current ratio above 1.0 gives RADX some near-term liquidity resilience, which can help it navigate reimbursement timing better than peers with tighter short-term coverage.

Overall Score

RADX shows some balance-sheet resilience, but weak cash conversion and negative interest coverage keep peer-relative execution and liquidity risks above average, limiting upside realization.